SEC Tracker
Get the app

Lexeo Therapeutics LXEO

Lexeo Therapeutics Appoints Kyle Rasback as Chief Financial Officer

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 99.1
Press release
  • Reports an executive or board change (5.02)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Lexeo Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. SELLAS Life Sciences Group SLS public float $219M, Jun 30, 2025
  2. Precigen PGEN public float $219M, Jun 30, 2025
  3. Perspective Therapeutics CATX public float $213M, Jun 30, 2025
  4. Rocket Pharmaceuticals RCKT public float $213M, Jun 30, 2025
  5. Natures Sunshine Products NATR public float $211M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.